Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11309266 | 0.86 | THRA (0.59) | PPARDTSHRTHRATHRBL3MBTL1 | |
| SCHEMBL21052036 | 0.85 | PPARD (0.74) | PPARDMAOB | |
| SCHEMBL5262606 | 0.84 | L3MBTL1 (0.50) | PPARDTHRATHRBL3MBTL1MAOB | |
| SCHEMBL3177267 | 0.84 | TSHR (0.61) | PPARDTSHRMCL1FFAR4L3MBTL1 | |
| SCHEMBL2214019 | 0.84 | MAOB (0.58) | PPARDCYSLTR2CYSLTR1FFAR4FFAR1 | |
| SCHEMBL1545582 | 0.83 | MAOB (0.51) | PPARDTHRATHRBL3MBTL1MAOB | |
| SCHEMBL18480008 | 0.83 | PKM (0.56) | PPARDL3MBTL1MAOB | |
| SCHEMBL8172211 | 0.83 | THRB (0.52) | PPARDTHRATHRBL3MBTL1MAOB | |
| SCHEMBL7404901 | 0.83 | MCL1 (0.64) | PPARDHTTCYSLTR2CYSLTR1TSHR | |
| SCHEMBL10262207 | 0.82 | THRA (0.50) | PPARDTHRATHRBL3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| CN-100384838-C | Novel benzylpiperidine compound | MITSUBISHI PHARMA CORP (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| CN-1505626-A | Novel benzylpiperidine compound | ������ҩ��ʽ���� | 2004-06-16 | — | — | CN | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | PPARD 1237/4885HTT 4507/4885CYSLTR2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.